Physicians' Academy for Cardiovascular Education

DPP-4 inhibitor safe for diabetic patients with renal dysfunction

Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOS

Literature - Engel SS, Suryawanshi S, Stevens SR, et al. - Diabetes Obes Metab. 2017; published online ahead of print

Main results

Conclusion

T2DM patients with CKD in the TECOS study had higher incidences of serious adverse events and diabetic complications compared with non-CKD participants. Compared to placebo, long-term treatment with sitagliptin was well tolerated in CKD participants, with no evidence of adverse impact on the safety endpoints in TECOS.

References

Show references

Find this article online at Diabetes Obes Metab.

Share this page with your colleagues and friends: